We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




New Test Reveals Existing Antibiotics Can Cure Superbugs

By LabMedica International staff writers
Posted on 02 May 2023
Print article
Image: A new AST has revealed that FDA-approved antibiotics can treat multidrug-resistant infections (Photo courtesy of Freepik)
Image: A new AST has revealed that FDA-approved antibiotics can treat multidrug-resistant infections (Photo courtesy of Freepik)

A new test has revealed that FDA-approved antibiotics, readily available at local pharmacies, can effectively combat superbugs. These antibiotics are not prescribed due to the gold-standard test indicating their inefficacy. This novel test could revolutionize the development, testing, and prescription of antibiotics, playing a crucial role in the battle against bacterial resistance by optimizing the use of existing antibiotics and bolstering the search for new ones.

The antibiotic study by a team of scientists at UC Santa Barbara (Santa Barbara, CA, USA) tackled a fundamental issue in the current healthcare approach to determining antibiotic resistance, which fails to consider the environmental conditions within the body that influence drug efficacy. By replicating these conditions, the new test pinpointed several effective antibiotics that standard testing had dismissed. When both the new and standard tests concurred, a near-perfect prediction of treatment success or failure emerged. The study involved extensive screening of over 500 antibiotic-bacteria combinations, with the findings indicating that the standard test is inaccurate approximately 15% of the time. Since doctors depend on this test to guide treatment decisions, it may result in the prescription of inappropriate antibiotics.

Medical professionals are aware of the gold-standard test's limitations. When the suggested antibiotics prove ineffective, physicians must draw upon their experience to determine the most suitable antibiotic(s) for their patients. This study offers a potential solution to bridge the gap between the antibiotics suggested by standard testing and actual patient outcomes. The new test could lead to substantial cost savings for the healthcare sector as they endeavor to identify novel drugs to combat antimicrobial-resistant infections.

“Reevaluation of FDA-approved antibiotics may be of far greater benefit than the time and cost of developing new drugs to combat antimicrobial resistance,” explained Santa Barbara Cottage Hospital physician Lynn Fitzgibbons, M.D., “potentially leading to significant life-savings and cost-savings.”

Related Links:
UC Santa Barbara 

Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Ultra-Low Temperature Freezer
iUF118-GX
New
Total Thyroxine Assay
Total Thyroxine CLIA Kit

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.